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An update on myasthenia gravis
K H Chan Fivf f. - S L Ho
Summary
Myasthenia gravis (MG) is an autoimmune disease
characterised by autoantibodies against acetylcholine
receptors at neuromuscular junctions, resulting in
defective neuromuscular transmission. The characteristic
features are fatigability and fluctuating weakness of
skeletal muscles. It commonly presents with diplopia or
unilateral ptosis, which are worse in the evenings.
Respiratory muscle weakness may result in respiratory
failure. MG is associated with various autoimmune
diseases, and thymic hyperplasia or thymoma. An early
diagnosis depends on a high index of suspicion, and is
confirmed using tensilon test, and electromyography
(EMG), and by a raised acetylcholine receptor antibody
titre. Symptomatic treatment consists of cholinesterase
inhibitors, corticosteroids and other immuno-
suppressants. Plasmapheresis or pooled intravenous
human IgG (IVIgG) provides rapid but short-term relief for
acute exacerbations. Thymectomy provides long-term
control for patients with thymic hyperplasia, and is
essential for thymomas.
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Introduction
Myasthenia gravis (MG) is an acquired autoimmune
neuromuscu la r j u n c t i o n (NMJ) disorder of skeletal
musc les . It is charac te r i sed by the p resence of
au toan t ibod ie s that bind to ace ty lcho l ine receptors
(AChR) at the postsynaptic membrane. Such autoantigen-
au toan t ibody interact ion leads to the des t ruc t ion of
n i co t in i c AChR at the NMJ. Congenital myasthenia
gravis is pathophysiologically different, caused by a non-
i m m u n o l o g i c a l a b n o r m a l i t y o f n e u r o m u s c u l a r
transmission. This following article will focus on
acquired MG only.
Clinical features
The characteristic cl inical features are fatigability
and f l u c t u a t i n g weakness of skeletal muscles . The
weakness can affect any voluntary muscles. The
commonly affected muscles are the levator palpebrae,
extraocular muscles, bulbar, facial, neck, limb and trunk
muscles. Respiratory muscles are usually involved in
severe MG and may lead to potentially life-threatening
respira tory fa i lu re . The most common present ing
symptoms are diplopia or unilateral ptosis that occurs in
about 50% of patients. Symptoms usually appear towards
the end of the day. The common clinical features are
listed in Table 1. Occasionally, the first symptom may
be weakness of finger or foot extensors, noticed, for
example, during piano playing and jogging. Rarely, it
may be diagnosed after prolonged postoperative apnoea
following the use of muscle relaxants. Precipitating
factors may include stress, infections, certain medications,
such as aminoglycosides and neuromuscular blockers such
as suxamethonium and atracurium, and in women,
menstruation1 and puerperium.2
(Continued on page 10)
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Table 1: Clinical features of myasthenia gravis
1) Fatigability
2) Fluctuating weakness of skeletal muscles — facial, neck, limb,
trunk
3) Eye signs — variable ptosis, ophthalmoplegia, diplopia
4) Bulbar weakness — dysar th r ia , dysphagia, weakness of
mastication, nasal speech
5) Respira tory musc le weakness — resp i ra to ry dis t ress ,
respiratory failure
6) Prolonged apnoea after use of muscle relaxants
7) Localised muscle atrophy in a small proportion of patients
Epidemiology
The prevalence of MG in Hong Kong Chinese is
about 60 per million and the incidence is about four per
million of population/year,3 compared to a prevalence of
32 to 90 per mi l l ion population, and an incidence of two
to six per m i l l i o n p o p u l a t i o n / y e a r in Japanese and
Caucasians.4'6 Women are affected twice as often as men,
but no significant gender difference in incidence exists
before puberty, or after the age 40 years.3'5-6 About 33%
of Chinese adult-onset patients have ocular MG. About
30% of MG pa t i en t s have mild disease, 25% have
moderately severe involvement, 12% have fulminant
disease and 1.3% have late severe disease. The mean age
at onset of symptoms in Hong Kong Chinese patients is
about 35 years.7 Chinese patients have a higher incidence
of ocular MG than Caucasians; 33% versus 13-20%.1
Associated autoimmune diseases
MG is associated with a number of autoimmune
diseases (Table 2). The most common association is with
thyroid diseases ( u s u a l l y h y p e r t h y r o i d i s m due to
thyroiditis). Some features in MG patients may be due
to the associated disease or its treatment rather than MG
per se. For example, muscle weakness may be due to
thyroid dysfunction. Ophthalmoplegia may be a feature
of Graves' disease. Rheumatoid arthritis patients treated
with penicillamine may develop drug-induced MG.8
Pathophysiology
The endplate contains 10 to 20 million AChR that are
densely packed at the interjunctional folds. (Figure 1).
AChR in a normal endplate is composed of five subunits
made up of four types of peptide chains — a, P, S and
e.10 Although most AChR antibodies are directed at
sequences of the a chain, they may bind to all the peptide
c h a i n s of the AChR. They d a m a g e AChR via
complement-mediated lysis," and by crosslinking the
receptors.1 2 The number and densi ty of AChR are
reduced,13 resulting in smaller EPP amplitudes and thus,
defective neuromuscular transmission.
Thymic abnormalities in MG
Thymic hyperplasia is found in more than 70% of
patients.14 About 15% of MG patients have a thymoma.'
In general, MG patients with thymoma have more severe
symptoms, and are more l i ke ly to be associated wi th
autoimmune diseases and extra thymic malignancies.
Diagnosis
The diagnosis of MG is based on clinical features,
and appropriate investigations (Table 3).
Table 2: Autoimmune diseases associated with myasthenia
gravis
1) Thyroid diseases
2) Rheumatoid arthritis
3) Systemic lupus erythematous
4) Scleroderma
5) Polymyositis
6) Sjogren's syndrome
7) Glomerulonephritis
8) Auto immune adrenalitis
9) Pernicious anaemia
10) Autoimmune thrombocytopenia
11) Haemolytic anaemia
12) Pure red cell anaemia, pancytopenia (almost exclusively
related to thymoma)
13) Ulcerative colitis, Crohn's disease
14) Sarcoidosis
15) Primary ovarian failure
16) Pemphigus
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Figure 1: Schematic diagram of the neuromuscular junction (NMJ)
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ChAT = choline acetyItransferase; CoA = coenzyme A. The neuromuscular junction consists of the motor nerve terminal, muscle endplate
with folded postsynaptic membrane, and synoptic cleft in between. Acelylcholine (ACh) is synthesised in the motor nerve and stored in
nerve terminal vesicles. When the terminal is depolarised, it results in calcium (Ca2+) influx9 that then releases ACh into the synaptic
cleft. ACh interacts with its receptors on the post-synaptic membrane, which results in an endplate potential (EPP). A sufficiently large
EPP spreads across the muscle fiber, initiating muscle contraction. ACh is then hydrolysed to choline and acetate by acetylcholinesterase
(AChE) located on the endplate membrane. The nerve terminal actively takes up choline for further synthesis of ACh.
Table 3: Investigations in myasthenia gravis
1) AChR antibody titre
2) Tensilon test
3) EMG: repetitive nerve stimulation
4) Single-fiber EMG for abnormal neuromuscular transmission
5) CT mediastinum for thymic hyperplasia and thymoma
Tensilon (Edrophonium chloride) test
Weakness in MG improves after intravenous
edrophonium chloride, a short-acting cholinesterase
inhibitor (ChEI). This test is most reliable for patients
with ptosis or nasal speech.15 However, false negative
tests may be seen in patients with early disease, severe
fluctuations in symptoms or muscle atrophy.15 The test
should be repeated after exercise or in the evening, if the
diagnosis is still strongly suspected. False positive tests
may occur in motor neurone disease (where there is
abnormal neuromuscular transmission caused by rapid
denervation), Guil lain-Barre syndrome, botul i sm,
Lambert-Eaton myasthenic syndrome, polymyositis,
cranial nerve syndromes with brainstem involvement,
tumours of the orbital or parasellar region and bilateral
intracavernous carotid aneurysm.16 The sensitivity of the
test is about 90% in both generalised and ocular MG,15
with a specificity of about 90%.16
(Continued on page 13)
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Typical cl inical features, e.g. ptosis, extraocular
movement, proximal limb power and forced vital capacity
may be serially monitored, before and after intravenous
injections of placebo (saline) or Tensilon in a double-blind
manner. For instance, 2mg is injected intravenously and
the response monitored for 1 minute, followed by 3 mg
and then 5 mg bolus, if there is no improvement. Rarely,
some patients may be very sensitive to the drug where
even small doses may cause serious side-effects such as
bradycardia and asystole.1 5 Hence, resusc i ta t ion
equipment should be available in case of an extremely
sensitive patient. In selected cases, a bolus intravenous
dose of atropine (0.6 mg) may be given prior to the test.
Other common side-effects of Tensilon are increased
lacrimation, nausea, salivation and abdominal cramps.
Acetylcholine receptor (AChR) antibody titre
Elevated serum titres of AChR antibodies are found
in about 80-90% of patients with generalised MG,'7'18 and
in about 60% of pure ocular MG patients.17 In Chinese,
these antibodies are present in about 70% of generalised
MG patients and in 30% of ocular MG.3 However,
seronegative tests do not exclude MG. Conversely,
se ropos i t i ve t e s t s a r e f o u n d in s y s t e m i c l u p u s
erythematosus, bi l iary cirrhosis, amyotrophic lateral
sclerosis, rheumatoid arthritis on penici l lamine, 8
haematological diseases, bone marrow transplantation,
thymoma without MG, tardive dyskinesia, in relatives of
MG patients, and in the elderly with other autoimmune
antibodies.18 Hence, presence of AChR antibodies per se
is not diagnostic of MG.
The antibody titre is not associated with the severity
of MG. However, during the course of the disease in an
individual patient, there is a good correlation between
antibody titre and cl inical improvement fol lowing
thymectomy in about 80% of patients.19 A similar
correlation is also found in response to plasmapheresis.20
Most patients remain seropositive, even in those with
complete remission.18 Seronegative patients are more
likely to have purely ocular symptoms and their clinical
features do not differ from seropositive patients.21 A
lower frequency of thymic pathology has been reported
for seronegative patients.22
Electromyography (EMG)
A decrease in compound muscle action potential
CMAP amplitude (> 10%; i.e. significant decremental
response) to repetitive nerve stimuli stimulation indicates
impaired neuromuscular transmission. The responses
from surface EMG may be recorded over the abductor
digiti minimus or from more proximal muscles such as
the trapezius. However, subjects wi th either mild
symptoms or pure ocular MG may show normal
responses. The sensitivity of the test ranged from about
30 to 90% in generalised MG, and about 4 to 50% in
ocular MG.16 The specificity of the test is about 90% for
generalised MG and is even higher for ocular MG. False
positive responses are observed in motor neurone disease,
myo ton i c dys t rophy , Lamber t -Ea ton myas then ic
syndrome and other myopathies. A conventional needle
EMG should also be performed in some cases to exclude
polymyositis and thyroid myopathy that may mimic or
coexist with MG.
Single-fiber (SF) EMG is the most sensitive test of
impai red n e u r o m u s c u l a r t r a n s m i s s i o n . SF-EMG
recordings are made while the patient voluntarily activates
the muscle being studied. When action potentials are
simultaneously recorded from two muscle fibers from the
same motor uni t , the time interval between the two
potentials varies among consecutive discharges. The
"jitter" is quantified as the mean difference between
consecutive interpotential intervals. When neuromuscular
transmission is impaired, the "jitter" is increased. Normal
"jitter" in a clinically weak muscle excludes abnormal
neuromuscular transmission as the cause of weakness.
Increased muscle "jitter" is found in almost all MG
subjects but is also found in other motor unit disorders
wi th defects in neuromuscular t ransmiss ion , e.g.
neuropathy and myopathy. Conventional needle EMG
should be performed when there is increased "jitter" to
exclude disorders such as polymyositis, Eaton-Lambert
syndrome, periodic paralysis, Miller-Fisher syndrome,
botulism, motor neurone disease or organophosphate
poisoning.
Based on the age of onset, thymic abnormalities and
other immune variables, generalised MG patients can be
divided into three main groups:
a) onset before 45 years (mainly female), usually
associated with thymic hyperplasia
b) onset after 45 years (slightly more males) usually
associated with thymic atrophy
c) patients with thymoma, usually with no clear age and
sex bias.
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According to severity of clinical features, MG can be
classified into five subtypes (Table 4).
Management
General principles
The treatment should aim to relieve symptoms and
achieve remission, to enable patients to return to their
normal activities. Treatment is divided into symptomatic
and immunomodu la t i ng therapies. (Table 5). The
treatment should be tailored to the individual patient.
ChEI are used for symptomatic control. If significant
or d i s a b l i n g symptoms persist despite optimal ChEI
therapy, corticosteroids should be considered when there
is no s igni f icant improvement six months to one year
postthymectomy. Long-term azathioprine is indicated if
they respond poorly to corticosteroids, or when high
m a i n t e n a n c e doses of co r t i co s t e ro id s are r equ i r ed .
Plasmapheresis or pooled intravenous human IgG (IVIgG)
provides rapid but short- term improvement for acute
exacerbations. Thymectomy is indicated for long-term
control for pa t ien ts w i t h t hymic hype rp l a s i a and is
essential for patients with thymomas. The patients and
their carers should be educated about MG, the need for
regular assessments, and prompt medical attention when
they deteriorate. Patients should carry a card l i s t ing
contraindicated medications (Table 6).
Symptomatic treatment
Cholinesterase inhibitor
C h E I i n h i b i t s t h e h y d r o l y s i s o f A C h b y
acetylcholinesterase at the synaptic cleft (Figure 1) such
that ACh can stay in the synaptic cleft and interact with
AChR for a longer duration. It may be the only drug that
is required in some patients. The dose has to be titrated
according to the response. The required dose may be
increased with infections, stress or even menstruation. An
optimal dose may be difficult to achieve in some patients
where different muscle groups respond differently to the
same dose of ChEI. We generally titrate the dosage to
produce responses in muscles that cause the greatest
symptomatic disabili ty. Pyridostigmine is most often
used because of its longer duration of action and may be
commenced at 30 mg three times daily. The side-effects
of ChEI are shown in Table 7.
Immunomodulating treatment
Thymectomy
More than half the patients with thymic hyperplasia
who underwent thymectomy had remission within two
years.2 3 A n o t h e r 33% became a s y m p t o m a t i c on
Table 4: Subtypes of myasthenia gravis
I. Pure ocular (ptosis, diplopia )
II A. Mild generalised (ocular and extremit ies , no prominent
bulbar signs)
II B. Moderate generalised (ocular and/or bulbar signs, variable
limb muscle involvement, and no crises)
I I I . Acute fu lmina t ing generalised signs with prominent bulbar
involvement and crises
IV. Late severe generalised and prominent bulbar s igns and
crises
(Osserman KE. Genkins G. Studies in myasthenia gravis: review of
a twenty-year experience in over 1,200 patients. J Mount Sinai Hosp,
l971;38:497-537.
Table 5: Modes of treatment for myasthenia gravis
1) General measures
2) Symptomatic t rea tment
— ChEI, physical aids and surgery for eye symptoms
3) Immunotherapy
— short-term: plasmapheresis, IVIgG
— long-term: corticosteroids, azathioprine, other immuno-
suppressants, and thymectomy
Table 6: Drugs which are contraindicated or used with
caution in myasthenia gravis
1) Aminoglycosides
2) D-penic i l lamine
3) N e u r o m u s c u l a r blockers ( s u x a m e t h o n i u m , a l c u r o n i u m ,
vecuronium, atracurium)
4) Local anaesthetics (e.g. lignocaine)
5) Anti-arrhythmic (e.g. quinine, quinidine, procainamide)
6) Beta-blockers
7) Magnesium sulphate
Note: High dose corticosteroids may initially worsen myasthenic
symptoms
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Table 7: Side-effects of cholinesterase inhibitors
1) Dose-related muscarinic effects
— gastrointestinal: nausea, vomiting, abdominal pain, and
diarrhoea
— resp i ra to ry : b ronchocons t r i c t ion , pharyngea l and
bronchial hypersecretion
— ocular: miosis. pain, conjunctival congestion, ci l iary
spasm, glandular hypersecretion
2) M a s s i v e overdose l eads to i m p a i r e d n e u r o m u s c u l a r
transmission, fat igabil i ty, increased weakness, fasciculations
-cholinergic crisis
3) Acute psychosis or bad dreams (bromism): rarely in patients
who take high doses of pyridostigmine bromide
pyridostigmine alone, and 11% were asymptomatic on
corticosteroids. The extent of thymic hyperplasia is
thought to correlate with the clinical response,23 but other
studies did not confirm this.24 Seronegative MG may also
improve with thymectomy.23
Thymec tomy i s i nd i ca t ed in a l l p a t i e n t s w i t h
thymoma and refractory symptoms, and in those less than
45 years old with generalised MG. Age per se is not a
contraindication for thymectomy and individual cases of
ocular MG patients may be considered. Control of MG
following thymectomy on patients with thymoma is less
clear. It may be impossible to resect some thymomas
completely. The prognosis is more related to the extent
of the tumour and is generally worse than those patients
without thymoma.23, 24
Corticosteroids
Steroids are indicated when symptoms are not well
controlled using ChEI. Pure ocular MG with disabling
s y m p t o m s uncon t ro l l ed wi th ChEI may respond
dramatically to low-dose steroids. At least 70% of MG
patients respond clinically to steroids.25 The improvement
usually begins after two weeks of therapy. We prefer to
use prednisolone instead of prednisone because the latter
requires hepatic conversion to prednisolone. Prednisolone
(60 to 80 mg daily) followed by lower dose alternate-day
therapy of several years duration, produced remission of
MG symptoms in about 30% of patients, and marked
improvement in about 50% within 18 months of therapy.25
Long-term improvement was obtained in 80% of patients.
About 15% of the subjects were able to discontinue the
steroids. About 20% of those who achieved satisfactory
response had exacerbations, which necessitated a return
to higher doses or other forms of treatment.25
We suggest a gradual dose increment starting at 5 mg
prednisolone daily with a weekly increase of 2.5 mg until
symptoms improve. Its maximum dose is usually 60 to
80 mg daily. When improvement is achieved, the dose
can be gradually reduced over months to the lowest dose
(preferably less than 10 mg daily) necessary to maintain
improvement. A dose reduction of more than 5 mg per
month may provoke a relapse of symptoms.26 Patients
w i t h bulbar weakness may be especially sensi t ive to
exacerbations when steroids are i n i t i a l l y given. Mi ld
early exacerbation developed in about half of the patients
ini t ia l ly treated with 60 to 80 mg daily oral prednisone,
and severe exacerbations occurred in under 10% of
patients.27 Hence, the dose of steroids should be increased
gradually.28 Plasmapheresis or IVIgG may be used to
provide short- term control over t h i s period. Other
immunosuppressants should be considered for patients
who require more than 15 mg prednisolone daily. Steroid-
induced hypokalaemia and myopathy can occasionally
mimic MG symptoms. Various measures i n c l u d i n g
calcium supplements may be taken to reduce long-term
side-effects of steroids in women.
Azathioprine
A z a t h i o p r i n e is converted in the l iver to
mercaptopurine, which possesses immunosuppressive and
anti-inflammatory properties. Azathioprine is useful for
its steroid-sparing effect, and should be considered in MG
when the response to steroids is unsatisfactory, or the
maintenance dose is greater than 15 mg prednisolone
daily. It may also be used if there is unsatisfactory
control with ChEI, or if steroids and/or thymectomy are
contraindicated or not tolerated. Azathioprine used in
combinat ion with prednisolone is more efficacious
compared to prednisolone alone. Adjunct azathioprine in
seropositive MG reduces the maintenance dose of
prednisolone and is associated with fewer treatment
failures, longer remissions, and fewer steroid-induced
side-effects.29 We suggest starting azathioprine at 25 mg
daily, with increments of 25 mg/week up to 100 mg/day
or 3 mg/kg/day. Azathioprine has a slow onset of action,
with a delay in therapeutic response of about six months.
At least half the patients will relapse during dose
reduction.30-32 The incidence of serious side-effects of
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azathioprine is low. Complete blood count and liver
func t ion tests should be monitored weekly during
init iat ion of therapy and thereafter every three to six
months. Side-effects of azathioprine include reversible
marrow depression, opportunistic infections, and transient
elevation of liver enzymes, acute idiosyncratic reaction
and teratogenicity. Taking divided doses after meals will
help to reduce gastrointestinal upset. Contraception is
recommended dur ing and for at least six months after
cessation of therapy.
Other immunosuppressants - cyclosporine and
cyclophosphamide
Cyclosporine is a potent immunosuppressant, which
may be considered in patients refractory to other forms
of immunosuppressant therapy.33 Plasma trough levels,
blood pressure, renal funct ion should be monitored
regularly with doses adjusted accordingly. Its long-term
use in MG is l imited by nephrotoxicity. Cyclophos-
phamide is an alkylating agent that interferes with B-cell
proliferation, hence suppresses antibody production.
Significant potential side-effects and toxicity limit its use
for refractory patients only.34 Its side-effects include
leukopenia, alopecia, dysuria, haemorrhagic cystitis,
teratogenicity, sterility.
Plasma exchange (Plasmapharesis)
P l a s m a p h a r e s i s r e m o v e s c i r c u l a t i n g AChR
antibodies. It acts rapidly35,36 with improvement seen in
more than 60% of acute MG cases.37-38 It may be used
for optimising control of MG prior to thymectomy, for
post-operative deterioration, and as a short-term adjunct
therapy to immunosuppressants in severely affected
patients. Intermittent plasmapheresis may be considered
for MG refractory patients who respond poorly to drugs
or thymectomy. It involves the separation of plasma,
which is then replaced with human albumin (5%) in saline
supplemented with calcium and potassium. Typically,
about 2 litres of plasma is exchanged per session, two or
three times a week until there is improvement, which may
occur within the first 24 hours. Often, the effects of
plasmapheresis are only obvious after two days. The
improvement may last for several weeks. There is no
c u m u l a t i v e b e n e f i t f r om r e p e a t e d c o u r s e s o f
plasmapheresis.36 The clinical response is correlated to
a reduct ion in AChR ant ibody titre.2 0 There is a
significant haemodynamic shift during plasmapheresis
that may lead to hypotension, especially in septicaemia
and haemodynamically unstable patients. Access to large
veins may be a problem in some patients requiring central
vein catheterization. Other potential side-effects include
a l l e r g i c r eac t ions to h u m a n a l b u m i n , e l e c t r o l y t e
d i s t u r b a n c e , t h r o m b o p h e l i t i s , subacute bac t e r i a l
endocarditis, pulmonary embolism and pneumothorax.
Intravenous immunoglobulin (IVIgG)
It acts by reducing the production and increasing the
clearance of autoantibodies.39 It also inhibits the binding
of ac t iva ted complement to target T-cells,4 0 t h u s
suppress ing complement-mediated motor end-plate
destruction. Clinical response was seen in about 70% of
pat ients , 4 1 , 42 and it serves an a l te rna t ive therapy to
plasmapheresis. IVIgG improves myasthenic symptoms
within a few days of treatment. The improvement usually
lasts up to 12 weeks.43 A regime is 0.4gm/kg body weight
per day for five consecutive days may be considered. A
randomized trial comparing the efficacy and tolerance
between plasmapheresis (three exchanges) and IVIgG
(0.4gm/kg/Day for three or five days) did not show a
significant difference in outcome.44 Potential side-effects
from IVIgG include transient f lu-l ike symptoms with
fever, chills, nausea, vomiting, headache and malaise in
the first 24 hours. The headache and nausea may improve
with slowing of the infusion. Other side-effects include
transmission of viral hepatitis, anaphylactic reactions
(especially in IgA deficiency), renal failure45 and aseptic
meningitis.46
Treatment in specific circumstances in myasthenia
gravis
Ocular myasthenia gravis
Ocular MG is generally associated with a less life-
threatening disease, but 30 to 70% of pat ients who
developed ocular symptoms at onset may develop
general ised disease.5 '47 '48 The r isk of developing
generalised disease is highest soon after onset. A
diagnosis of ocular MG is usually made only if symptoms
remain ocular after two years. About 45 to 70% of ocular
MG patients are seropositive.17 '49 The pathogenesis,
associated diseases and treatment strategy of ocular MG
are similar to that of generalised MG. However, severe
diplopia can be very d isabl ing . Chronic ptosis and
diplopia may benefit from simple appliances, spectacle
modifications and prisms.
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MG associated with thymoma
M G p a t i e n t s w i t h t h y m o m a s h o u l d h a v e
thymectomy. 5 0 For non-invasive thymomas, radical
thymectomy is considered curative although follow-up CT
thorax should be performed. Invasive thymomas should
be considered for post-operative radiotherapy.
Myasthenic crisis
MG crisis involves a rapid and severe deterioration
of symptoms (within days), often with bulbar weakness
and respiratory failure that require mechanical ventilation.
It is a neurological emergency. The crisis often involves
a mixture of myasthenic and cholinergic features, where
the patient may take large doses of ChEI but the most
affected muscles (usually the bulbar and respiratory) do
not improve resu l t ing in typ ica l c l i n i c a l fea tures
(Table 8). It is more common in patients with thymoma.
The Tensilon test is unhelpful in distinguishing the
different types of crises as d i f ferent muscle groups
respond differently. It is also risky as the patient may
deteriorate further. The patient w i l l require assisted
ventilation and airway protection, and should be managed
in an Intensive Care Uni t . The conscious state,
respiratory status including respiratory rate, forced vital
capacity (FVC), continuous pulse oximetry and arterial
blood gases, cardiovascular status and muscle strength
should be monitored regularly. Anticipation and prompt
respiratory support are vital as dysphagia, copious
production of bronchial secretions and aspiration can
Table 8: Clinical features of myasthenic crisis
1) Cholinergic crisis
— nicotinic overactivity (e.g. fasciculation, muscle cramps,
muscle weakness)
— muscarinic overactivity (e.g. abdominal cramps, diarrhoea,
meiosis , p rofuse s a l i va t i on , b r o n c h i a l secre t ion ,
lacrimation)
2) Myasthenic weakness
— ptosis, diplopia
— generalised limb and trunk weakness
— respiratory muscle weakness with hypoventilation
— facial and pharyngeal weakness resulting in dysphagia and
dysarthria
— facial diplegia, aspiration
3) Confusion due to hypercapnia and/or hypoxaemia
rapidly develop and further exacerbate respiratory failure.
Assis ted v e n t i l a t i o n is requi red if FVC is below
15 ml/kg-body weight or when the tidal volume drops to
below 4 to 5 ml/kg body weights. ChEI may be stopped
when the patient is ventilated, and restarted at lower
doses, and readjusted according to the clinical response.
Improvement may occur with just supportive measures,
but it is expedited with plasmapharesis or IVIgG.43-51
Appropriate invest igat ions should be carried out to
determine any precip i ta t ing factors, e.g. in fec t ion ,
aspiration pneumonia, surgery, initiation of high doses of
s teroids and ove r - r ap id w i t h d r a w a l of i r n m u n o -
suppressants. In about 30% of MG crisis, no precipitating
factor is found.53
Mortality from myasthenic crisis has declined from
over 40% in the early 1960s to about 5% in 1970s.52 High
pre-intubation serum bicarbonate level, small peak vital
capacity, and age of above 50 years are predictors of
prolonged intubation." Poor functional outcome and
mortality are related to co-existing medical conditions.53
Anaesthetic management
Stress during operations and certain drugs (e.g.
narcotics and sedatives) used perioperatively may
exacerbate MG. Local and spinal anaesthesia are
preferred over inhalational anaesthesia. Inhalational
agents alone usually offer adequate muscle relaxation.54
Depolarising neuromuscular blockers should be avoided
if possible, as low doses may cause pronounced and long-
lasting blockade. If neuromuscu la r blockers are
necessary, a non-depolarising agent (e.g. alcuronium,
vecuronium, atracurium) should be used at one tenth to
half of the normal dose under careful monitoring.55 These
agents are eliminated rapidly, and hence can be titrated
during surgery. A longer period of postoperative
ventilatory support may be required even for patients with
good pre-operative control of MG.
Myasthenia gravis in pregnancy
The t r ea tmen t of pe r ina t a l c o n d i t i o n s , e.g.
preeclampsia, preterm labour and infection may be altered
in MG. The clinical course of MG in pregnancy is
unpredictable even in individuals with stable disease.
About 1/3 of patients improve, 1/3 deteriorate and the
remaining 1/3 remain stable. Exacerbations in MG may
(Continued on page 19)
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Key messages
1. Myasthenia gravis (MG) is an autoimmune disease
associated with autoantibody-mediated destruction of
nicotinic acetylcholine receptors in skeletal muscles
and impaired neuromuscular transmission.
2. Consider the diagnosis of MG in patients with ptosis
and diplopia, dysarthria, dysphagia and limb weakness,
typically proximal.
3. Fluctuating symptoms and muscle fatigability are
important clues to the diagnosis.
4. Associated autoimmune diseases, thymic hyperplasia
and thymoma should be considered and screened for.
5. The management should aim at symptom-free
remission or mild symptoms with satisfactory quality
of life.
6. Acute exacerbation in MG, especially those involving
respiratory distress and bulbar weakness, must be
referred for intensive care, and may require intubation
and ventilatory support.
occur in all three trimesters. The clinical course of one
pregnancy does not predic t t h a t of s u b s e q u e n t
pregnancies. Therapeutic abortions do not help to control
MG in first-trimester exacerbations.56'57
Counse l l i ng should be ca r r i ed out pr ior to
conception. Steroids and other immunosuppressants may
be discontinued or stopped. Cytotoxic agents are
contraindicated during pregnancy due to potential
t e r a t o g e n i c i t y bu t s te ro ids may be c o n t i n u e d .
Exacerbations are more frequent for patients without
thymectomy prior to pregnancy. The prevalence of
neonatal MG is not affected by thymectomy.58 However,
thymectomy is rarely performed during pregnancy, as the
long-term outcome of MG is not affected by a delayed
operation. Plasmapheresis and IVIgG may be considered
in exacerbations or MG crisis during pregnancy. The
uterus consists of smooth muscle. Its contractions are not
mediated by nicotinic ACh receptors and hence are
unaffected in MG. However, the voluntary expulsion of
the fetus involves skeletal muscles during the second stage
of labour and this may be compromised in MG. Regional
anaesthesia and pudendal block may be performed for
pain relief and caesarean section. Medications that
potentiate myasthenic weakness should be avoided if
possible. Magnesium sulphate may exacerbate MG
symptoms and is contraindicated for pre-eclampsia.59
Transient MG affects 10 to 20% of neonates.2
Affected newborns feed poorly during the first three days
and present with a feeble cry, inadequate sucking,
generalised muscle weakness, and respiratory distress,2
Symptoms last for an average period of three weeks
although it may continue for up to 12 weeks. Close
observation, supportive measures, and ChEI may be
required. The risk of neonatal MG is unrelated to
mate rna l MG s t a tus or AChR ant ibody ti tres.6 0
Myasthenic mothers may breast-feed the baby. In severe
postpartum exacerbations, maternal AchR antibodies may
pass to the infant through breast milk, and hence may
exacerbate neonatal MG. It may be reasonable to avoid
breast-feeding if symptoms of neonatal MG develop.
Muscarinic symptoms have been described in infants of
mothers taking ChEI.61
Role of family practitioners in the treatment of MG
Many patients with MG present with typical clinical
features but some cases may be easily misdiagnosed. The
diagnosis should always be considered in any patient
presenting with diplopia, ptosis, and bulbar or proximal
muscle weakness. Diurnal variations in the symptoms
should raise a high index of suspicion. A definitive
diagnosis should be established as early as possible.
Patients with suspected MG presenting with acute
respiratory distress and bulbar dysfunction should be
referred to neurological units urgently. The co-existence
of other a u t o i m m u n e diseases should a lways be
considered in any MG patient, even in those who have had
the disease for a long time. Patients, especially with
generalised symptoms, must be screened for thymic
hyperplasia and thymoma. Some MG patients may be
refractory to treatment and should be referred for further
management by a neurologist. •
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